Cryoport, Inc. — Q1 2024 Form 10-Q
Business context and period. Cryoport provides global temperature-controlled logistics, storage, bioprocessing and cryogenic products for life sciences customers. This unaudited report covers the three months ended March 31, 2024; comparisons are with Q1 2023 unless otherwise noted. Cryoport supported 675 clinical trials, including 77 in Phase 3, and 14 commercial therapies at quarter-end.
Financial performance
| Metric | Q1 2024 | Q1 2023 / comparator |
|---|---|---|
| Revenue | $54.6 million | $62.8 million; down 13.1% |
| Gross profit / margin | $21.8 million / 39.9% | $27.1 million / 43.1% |
| Operating loss | $21.3 million | $10.0 million |
| Net loss | $18.9 million; $0.43 per share attributable to common stockholders | $5.6 million; $0.16 per share |
| Adjusted EBITDA (non-GAAP) | $(7.7) million | $2.9 million |
| Operating cash flow | $(3.3) million | $2.8 million |
| Cash and short-term investments | $448.5 million | $456.8 million at December 31, 2023 |
| Working capital | $476.7 million | At March 31, 2024 |
Life Sciences Services revenue rose 2.6% to $36.8 million, while Life Sciences Products revenue fell 34.0% to $17.8 million. Services gross margin declined to 41.3% from 46.8%; products gross margin declined to 37.0% from 38.2%. SG&A increased 15.2% to $38.3 million and engineering and development expense increased 22.6% to $4.8 million.
Investing activities provided $6.4 million, principally reflecting investment maturities net of purchases; capital expenditures were $4.0 million. Financing activities provided $0.5 million. Cash and cash equivalents ended the quarter at $49.7 million.
Debt, liquidity and balance sheet
- Convertible senior notes had $385.5 million principal outstanding: $14.3 million due in 2025 and $371.2 million due in 2026. Their net carrying value was $379.2 million.
- Total liabilities were $470.7 million and stockholders’ equity was $472.2 million at March 31, 2024. Operating lease liabilities totaled $33.2 million; finance lease liabilities totaled $1.2 million.
- Management believes cash, investments and projected cash flows are sufficient for operational and capital needs for at least the next 12 months, while noting that additional capital may be needed until sustained profitability is achieved.
Material changes and management commentary
- The revenue decline was primarily driven by lower demand for cryogenic freezer systems, particularly in China. Services growth, including commercial cell and gene therapy revenue, partly offset the product decline.
- Management cited investment in business capabilities, facilities, technology and acquisitions as drivers of higher operating expenses. Two IntegriCell centers of excellence in Houston and Liège were expected to be qualified and operational in the second half of 2024.
- Q1 2023 included a $2.6 million gain related to the New Prague fire insurance claim; no comparable gain was recorded in Q1 2024. The fire-related revenue impact was estimated at $9.4 million, primarily in Q1 2022.
- Foreign exchange had minimal effect on reported Q1 revenue versus constant currency, although management said a stronger U.S. dollar had adversely affected operations and cash flows in EMEA and APAC. Foreign currency translation reduced comprehensive income by $2.0 million.
- The filing gives no specific quantified revenue or earnings guidance. Management expects significant expenses and operating losses in the near term while investing in growth initiatives.
Risks, contingencies and unusual items
- Inflation may raise labor, materials, transport and supplier costs; management reported some gross-margin impact and warned that future performance could be affected if cost increases are not offset by pricing or productivity.
- Investment portfolio values are exposed to interest-rate movements. The company reported $100.4 million in mutual-fund equity securities and $298.5 million in available-for-sale debt securities; it did not consider the reported unrealized debt-security losses to be credit losses.
- Foreign currency exposure includes $31.5 million of foreign-denominated cash and foreign-currency intercompany loans. The filing provides sensitivity estimates for adverse exchange-rate changes.
- Contingent consideration was $9.8 million at quarter-end and depends on future performance targets; estimates rely on unobservable assumptions and actual results may differ.
- A future Santa Ana facility lease is scheduled to commence in 2025, with aggregate rent of $27.7 million over 10 years; it is not included in the reported lease liabilities at quarter-end.
- The company reported no legal proceedings it believed would have a material adverse effect, no defaults on senior securities, and no material changes in internal control. Disclosure controls were deemed effective.
Most important facts for investors to verify
- Whether the decline in cryogenic-products demand, particularly in China, continues and how it affects revenue and margins.
- Whether services growth and the clinical-trial pipeline convert into sustained commercial revenue and improved profitability.
- Cash consumption, planned investment and capital needs relative to management’s stated 12-month liquidity outlook.
- Debt maturity and conversion terms, potential dilution, and the impact of the Series C preferred dividend. Approximately 18.2 million common shares were reserved for potential issuance at quarter-end.
- Execution, timing and costs of the IntegriCell centers and the future Santa Ana lease, as well as acquisition integration and contingent-payment obligations.